Name: Jeffry P. Simko, MD, PhD

University of California San Francisco
CURRICULUM VITAE
Name:
Jeffry P. Simko, MD, PhD
Positions:
Professor of Clinical Pathology, Step 1 (effective 7/1/13)
Department of Anatomic Pathology, School of Medicine
Prepared: 1-14
Professor of Clinical Pathology, Department of Urology (secondary)
Professor of Clinical Pathology, Dept. of Radiation Oncology (secondary)
Associate, UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC)
Director, Genitourinary Program Tissue Core (HDFCCC)
Chair, UCSF Genitourinary Tissue Utilization Committee (HDFCCC)
Associate Director, RTOG Biospecimen Resource (An NCI Sponsored National
Cooperative Group Resource)
Address:
Room B-620, Box 1785
UCSF Mount Zion Medical Center
1600 Divisadero Street
San Francisco, CA 94115-1785
Ph: (415) 353-7581
Pg: (415) 443-0534
FAX: (415) 353-7276
Email: jeff.simko@ucsf.edu
http://www.ucsf.edu/pathol/people/simko.htm
http://cc.ucsf.edu/people/simko_jeffry.html
EDUCATION:
1981-1985
1985-1990
1992-1996
1996-2000
2000-2001
2001-2002
University of Delaware, Newark, DE
University of North Carolina, Chapel Hill, NC
University of North Carolina, Chapel Hill, NC
University of California, San Francisco, CA
Harvard Medical School, Boston, MA
University of California, San Francisco, CA
B.S.
Ph.D.
M.D.
Resident
Fellow
Fellow
Chemistry
Analytical Chemistry
Medicine
Pathology
Molecular Pathology
Surgical Pathology
LICENSES, CERTIFICATION:
1998 -now
2000
2003
Medical License (#A064515), Medical Board of California, Sacramento, CA
Board Certification, Anatomic & Clinical Pathology (#00-309), Am. Board of Pathology
Board Certification, Molecular Genetic Pathology (#1921), American Board of Pathology
PRINCIPAL POSITIONS HELD:
Jeff Simko
1983-1985
1988-1990
1991-1992
2002-2003
2003-2007
2003-2007
2007 – 2013
2007 – 2013
2011 – 2013
2013 - now
2013 - now
2013 - now
Student Employee, Pioneering Research Lab, E.I. du Pont Inc., Wilmington, DE
Visiting Engineer, IBM T.J. Watson Research Center, Yorktown Heights, NY
Research Associate, Frontier Research Program, Institute of Physical and
Chemical Research (RIKEN), Wakou-shi, Saitama, Japan
Assistant Clinical Professor, Dept. of Anatomic Pathology, UC San Francisco
Assistant Professor of Pathology, Dept. of Anatomic Pathology, UC San Francisco
Assistant Professor of Pathology, Department of Urology, UC San Francisco
Associate Professor of Pathology, Dept. of Anatomic Pathology, UC San
Francisco
Associate Professor of Pathology, Department of Urology, UC San Francisco
Associate Professor of Pathology, Department of Radiation Oncology, UCSF
Professor of Pathology, Deptartment of Anatomic Pathology, UC San Francisco
Professor of Pathology, Department of Urology, UC San Francisco
Professor of Pathology, Department of Radiation Oncology, UCSF
OTHER POSITIONS HELD CONCURRENTLY (Pathology):
2000-2001
2001-2002
2000 - 2003
2002 - 2003
7/2002
2002 – present
2002 – present
2002 - present
8/2003
2004
2008 – 2010
2008 – now
2010 – now
2010 – 2012
Clinical Fellow, Molecular Pathology, Brigham and Womens’ Hospital, Boston, MA
Clinical Fellow, Surgical Pathology, UCSF Hospitals, San Francisco, CA
Consultant, Anatomic Pathology, Chiron Corporation, Emeryville, CA
Consultant, Anatomic Pathology, Incyte Genomics Corporation, Palo Alto, CA
Mini-Fellowship, Genitourinary Pathology, with Dr. Victor Reuter, Memorial
Sloan-Kettering Cancer Center, New York, NY
Director, Genitourinary Tissue Core, UCSF Comprehensive Cancer Center
Chair, Genitourinary Tissue Utilization Committee, UCSF
Staff Pathologist, UCSF Department of Anatomic Pathology
Mini-Fellowship, Genitourinary Pathology, with Dr. Jonathan Epstein, Johns
Hopkins Medical Institutions, Baltimore, MD
Co-Director, Molecular Pathology Laboratory, UCSF Departments of Anatomic
Pathology and Laboratory Medicine
Chair, South bay Pathology Society (SBPS) Nominating Committee
Associate Director, RTOG Biospecimen Resource (Radiation Therapy Oncology
Group), An NCI Sponsored National Cooperative Group Resource
ALLIANCE Pathology Group Cadre Member Pathologist (An NCI Sponsored
National Cooperative Group).
Director, Department of Anatomic Pathology Genitourinary Fellowship Program
OTHER EXPERIENCE (Non-pathology)
1986-1990
1993
1993-1994
9/94 - 12/94
Research Assistant, University of North Carolina Chapel Hill Chemistry Department
Medical Student Researcher, Department of Biochemistry, UNC School of Medicine
Medical Student Researcher, Dept. of Maternal and Fetal Med, UNC School of Med.
Visiting Scientist, Department of Biophysics, Beijing Medical University, P.R. China
HONORS AND AWARDS:
1
Jeff Simko
1984
1994
1994
1994
10/97-12/97
4/98-6/98
3/00-6/00
2000
American Chemical Society, U. of Delaware Analytical Chemistry Award
Howard Hughes Trust Fund Fellowship, University of North Carolina SOM
UNC School of Medicine Foreign Fellowship Award
Medical Alumni Association Research Fellowship, UNC School of Medicine
Chief Resident, Department of Anatomic Pathology, SF VA Medical Center
Chief Resident, Department of Anatomic Pathology, SF General Hospital
Chief Resident, Department of Laboratory Medicine, SF General Hospital
Travel Award, College of American Pathologists Strategic Science Seminar
KEYWORDS/AREAS OF INTEREST:
General Surgical Pathology, Genitourinary Pathology. Urologic Oncology. Molecular Pathology, Molecular
Diagnostics and Biomarkers of Malignancies, including tumor antigens and antibodies. Radiology-Pathology
Correlations in Genitourinary Malignancy. Tissue Banking
PROFESSIONAL ACTIVITIES
SUMMARY OF CLINICAL ACTIVITIES
2002 - now Surgical Pathology Clinical Service, UCSF Department of Anatomic Pathology
(evaluation and case sign-out of UCSF patient surgical and biopsy specimens, intra-operative
consultations and frozen sections, outside consultations sent to me from community
pathologists; ~20 weeks per year)
2002 - now
2002 – now
meetings/year
2002 – 2007
2004
2006 – 2007
2006 – now
2010 – now
Surgical Pathology On-Call Service, UCSF Mount Zion Cancer Center, 7 weeks/year
Urologic Oncology Tumor Board, UCSF Mount Zion Cancer Center, 24
Thoracic Oncology Tumor Board, UCSF Mount Zion Cancer Center, ad hoc, ~3 / year
Co-Director, Molecular Pathology Laboratory, UCSF Clinical Laboratory.
Proctor, Molecular Pathology Laboratory Clinical Faculty.
Head & Neck Tumor Board, UCSF Mount Zion Cancer Center, ad hoc, ~ 3 / year
Proctor, New Surgical Pathology Clinical Faculty.
My clinical service responsibilities are three-fold. First, is participation in the general surgical
pathology service for the Medical Center, and involves evaluation of tissue specimens (surgical and
biopsy specimens) taken from patients undergoing procedures at UCSF. This evaluation includes
general histology, immunohistochemistry and special stains, and intra-operative consultations and
frozen section diagnosis, with reports generated and distributed to clinicians for patient care. This
also involves on-call service for pathologic diagnosis during off-hours. My general surgical
pathology service, and my on-call service involve 14 weeks per year and 9 weeks per year
respectively. My second responsibility is as the specialist in genitourinary pathology, and involves
participation in urologic oncology tumor board and quality control of urologic oncology surgical and
biopsy specimen handling and sign-out. I’m also a consultant on challenging pathology cases related
to genitourinary oncology , which takes ~7 weeks/year in aggregate. This involves review of cases
from within and outside UCSF, where I’ve been solicited to render an opinion on a case due to my
expertise and experience within this area of pathology. I was also the proctor for faculty responsible
for the clinical molecular pathology laboratory (the Medical Director of this Lab, as well as others),
and I’m currently serving as the proctor for new faculty and clinical instructors (usually from one to
four individuals per year) involved in Surgical Pathology case sign-out at Mount Zion. This
involves review of all of their genitourinary pathology cases for three months each year.
2
Jeff Simko
PROFESSIONAL ORGANIZATIONS
Memberships
1991 – 1992
1992 – 1996
2001 – now
2001 – now
2001 – 2010
2004 – now
2005 – now
2006 - now
2009 – 2010
pending
Member, Japan Applied Physics Society (JAPS)
Member, American Medical Student Association (AMSA)
Member, US and Canadian Academy of Pathology (USCAP)
Fellow, College of American Pathologists (CAP)
Fellow, American Society of Clinical Pathologists (ASCP)
Associate Member, South Bay Pathology Society (SBPS)
Regular member, California Society of Pathologists (CSP)
Associate Member, American Urologic Association (AUA)
Regular Member, American Association of Cancer Research (AACR)
International Society of Urologic Pathologists (ISUP)
SERVICE TO PROFESSIONAL PUBLICATIONS:
1992 – 1996
2002 – now
2004
2005
2005
2006
2007 – 2008
2007 – 2011
2010 – now
2012 – now
Associate Editor, FAX: The Medical Student Research Journal (UNC-SOM)
Ad hoc referee, Journal of Urology (20 manuscripts in 12 years)
Ad hoc referee, J. National Comprehensive Cancer Network (1 manuscript in 1 year)
Ad hoc referee, American Journal of Pathology (1 manuscript in 1 year)
Ad hoc referee, Human Pathology (1 manuscript in 1 year)
Ad hoc Referee, Archives of Pathology and Laboratory Medicine (1 script in 1 year)
Ad hoc Referee, Journal of Molecular Diagnostics (3 manuscripts in 2 years).
Ad hoc Referee, European Journal of Urologic Pathology.
Ad hoc Referee, Urology Journal (6 manuscripts in 3 years).
Ad hoc Referee, British Journal of Urology International (1 manuscript in 1 year).
INVITED PRESENTATIONS
International
2005
3rd Annual Congress of International Drug Discovery Science and Technology
(IDDST), Shanghai, PR China
2006
4th Annual Congress of IDDST, Dalian, PR China
National
2008
2009
2009
2010
2012
2012
2013
2013
Pathobiology of Cancer: The Ed Smuckler Memorial Course AACR, Snowmass, CO
Pathobiology of Cancer: The Ed Smuckler Memorial Course AACR, Snowmass, CO
RTOG Semiannual Meeting, Philadelphia, PA (RTOG Tissue Banking Efforts)
American College of Osteopathic Pathology, National Meeting, San Francisco, CA
RTOG Semiannual Meeting, Atlanta GA (Tissue Banks in the Cooperative Groups)
RTOG Semiannual Symposium Organizer, Philadelphia (Next Gen Sequencing in
Cooperative Group Settings)
RTOG Semiannual Meeting, San Diego, CA
RTOG Semiannual Meeting, Philadelphia, PA
Regional and other Invited Presentations
2004
Current Issues in Anatomic Pathology, San Francisco, CA
2004
UCSF Department of Radiation Oncology Grand Rounds, San Francisco, CA
3
Jeff Simko
2005
2005
2006
2006
2008
2010
2011
2012
2013
2013
Current Issues in Anatomic Pathology, San Francisco, CA
City of Hope National Medical Center, Duarte, CA
Current Issues in Anatomic Pathology, San Francisco, CA
Beijing Medical University, Beijing, PR China
Current Issues in Anatomic Pathology, San Francisco, CA
Current Issues in Anatomic Pathology, San Francisco, CA
Guest Professor, Department of Pathology, University of Hawaii Medical School
Current Issues in Anatomic Pathology, San Francisco, CA
Visiting Professor, Grand Rounds, Department of Pathology, Harbor-UCLA Med Ctr.
Current Issues in Anatomic Pathology, San Francisco, CA
CME COURSES ATTENDED
2002
2003
2003
2003
2003
2004
2004
2004
2004
2004
2005
2005
2006
2006
2006
2006
2006
2006
2007
2007
2007
2007
2007
2007
2007
2008
2008
2008
2008
2008
2008
2009
2009
2009
Diagnostic Pathology of Soft Tissue Tumors, Harvard Medical School, Boston, MA
Weekends of Pathology, American Society of Clinical Pathology, San Francisco, CA
American Urological Association Annual Meeting, Chicago, IL
Current Issues in Anatomic Pathology, UCSF-Stanford, San Francisco, CA
California Society of Pathologist’s Annual Meeting, San Francisco, CA
Current Issues in Anatomic Pathology, UCSF-Stanford, San Francisco, CA
US and Canadian Academy of Pathology (USCAP) Annual Meeting, Vancouver, BC
Advances in Urology, UCSF, San Francisco, CA
South Bay Pathology Society Annual Spring Meeting, Monterey, CA
California Society of Pathologist’s Annual Meeting, San Francisco, CA
South Bay Pathology Society Annual Spring Meeting, Monterey, CA
Current Issues in Anatomic Pathology, UCSF-Stanford, San Francisco, CA
ASCO Prostate Cancer Symposium, San Francisco, CA
Controversies in Prostate Cancer Detection, UT MD Anderson, Kohala, HI
South Bay Pathology Society Annual Spring Meeting, Monterey, CA
Current Issues in Anatomic Pathology, UCSF-Stanford, San Francisco, CA
American Society of Clinical Pathology Annual Meeting, Las Vegas, NV
California Society of Pathology Annual Meeting, San Francisco, CA
Current Controversies in Urologic Oncology, UCSF Dept of Urology, SF, CA
Weekends of Pathology, American Society of Clinical Pathology, Las Vegas, NV
Early Stage Prostate Cancer Management, UCSF Dept of Urology, San Francisco, CA
US and Canadian Academy of Pathology (USCAP) Annual Meeting, San Diego, CA
South Bay Pathology Society Annual Spring Meeting, Monterey, CA
Current Issues in Anatomic Pathology, UCSF-Stanford, San Francisco, CA
Association of Molecular Pathology Annual Meeting, Los Angeles, CA
ASCO Genitourinary Cancer Symposium, San Francisco, CA
Current Issues in Anatomic Pathology, UCSF-Stanford, San Francisco, CA
South Bay Pathology Society Annual Spring Meeting, San Francisco, CA
RTOG Semiannual meeting, San Diego, CA
RTOG Semiannual meeting, Philadelphia, PA
California Society of Pathology Annual Meeting, Los Angeles, CA
RTOG Semiannual Meeting, New Orleans, LA
UCSF Department of Urology Annual CME Course, San Francisco, CA
US and Canadian Academy of Pathology (USCAP) Annual Meeting, Boston, MA
4
Jeff Simko
2009
2009
2010
2010
2010
2010
2010
2010
2010
2011
2011
2011
2011
2012
2012
2012
2012
2012
2012
2012
2013
2013
2013
2013
2013
2013
2013
2014
2014
2014
South Bay Pathology Society Annual Spring Meeting, Monterey, CA
RTOG Semiannual Meeting, Chicago, IL
RTOG Semiannual Meeting, Tampa, FL
ASCO GU Oncology Symposium, San Francisco, CA
USCAP Annual Meeting, Washington DC
RTOG Semiannual Meeting, Philadelphia, PA
Current Issues in Anatomic Pathology, San Francisco, CA
California Society of Pathology Annual Meeting, San Francisco, CA
CTTR Annual Symposium, San Francisco, CA
RTOG Semiannual Meeting, San Diego, CA
Current Issues in Anatomic Pathology, San Francisco, CA
RTOG Semiannual Meeting, Philadelphia, PA
California Society of Pathology Annual Meeting (San Francisco, CA)
RTOG Semiannual Meeting, Atlanta, GA
ASCO Genitourinary Symposium (San Francisco, CA)
USCAP Annual Meeting (Vancouver, BC, CN)
Current Issues in Anatomic Pathology, San Francisco, CA
RTOG Semiannual Meeting, Philadelphia, PA
Association of Molecular Pathology Annual Meeting, Long Beach, CA
California Society of Pathology Annual Meeting, San Francisco, CA
RTOG Semiannual Meeting, San Diego, CA
AUA Annual Meeting, San Diego, CA
Southbay Pathology Society Annual Meeting, Monterey, CA
Current Issues in Anatomic Pathology, San Francisco, CA
RTOG Semiannual Meeting, Philadelphia, PA
California Society of Pathology Annual Meeting (San Francisco, CA)
California Tumor Tissue Registry Semi-Annual Seminar (San Francisco, CA)
NRG (RTOG) SemiAnnual Meeting, San Diego, CA
ASCO Genitourinary Symposium (San Francisco, CA)
USCAP Annual Meeting (SanDiego, CA)
UNIVERSITY AND PUBLIC SERVICE
UNIVERSITY SERVICE
SCHOOL OF MEDICINE
HOSPITAL / MEDICAL CENTER SERVICE
2002 - now Surgical Pathology Clinical Service, UCSF Department of Pathology, 20 weeks/year
2002 - now Surgical Pathology On-Call Service, UCSF Mount Zion Cancer Center, 7 weeks/year
2002 – now Urologic Oncology Tumor Board, UCSF Mount Zion Cancer Center, 25
meetings/year
2002 – 2006 Thoracic Oncology Tumor Board, UCSF Mount Zion Cancer Center, ad hoc, ~2 / year
2004
Co-Director, Molecular Pathology Laboratory, UCSF Clinical Laboratory.
2006 – 2008 Gynecologic Tumor Board, UCSF Mount Zion Cancer Center, ad hoc, ~ 2 / year.
2006 – 2007 Proctor, Molecular Pathology Clinical Faculty.
2007 – now Gastrointestinal Tract Tumor Board, UCSF Mount Zion Cancer Center, ~ 3 / year.
2010 – now Proctor, New Surgical Pathology Clinical Faculty.
5
Jeff Simko
UCSF COMPREHENSIVE CANCER CENTER SERVICE
2002 – now
2002 – now
2002 – now
2002 – 2008
2002 – now
2007
Member, Genitourinary Oncology Program
Chair, UCSF Genitourinary Tissue Utilization Committee
Director, Genitourinary Oncology Program Tissue Core
Member, UCSF Prostate SPORE Project and Core Leaders Group
Member, Tissue Shared Resources Oversight Committee
Member, Academic Recruitment Search Committee
DEPARTMENT OF ANATOMIC PATHOLOGY SERVICE:
2002 – 2004 Consultant, Molecular Pathology Laboratory Development
2004
Member, Department of Anatomic Pathology Faculty Search Committee
2006 – 2007 Proctor, Molecular Pathology Clinical Faculty
2010 - 2012 Director, Urologic Pathology Fellowship
2010 – now Proctor, New Surgical Pathology Clinical Faculty.
2013
Member, Department of Anatomic Pathology Faculty Search Committee
DEPARTMENT OF UROLOGY SERVICE:
2008 - now
2010
2013
Director, Bimonthly Urology-Pathology Case Correlation Conference
Member, Faculty Search Committee
Member, Faculty Search Committee
GOVERNMENT and OTHER PROFESSIONAL SERVICE:
2003-2008
2004-2005
2005-now
2007-2008
2008 – now
2008 – 2010
2009-2010
2010 – 2011
2010 – now
2010 – now
2010 – now
2013 – now
Representative, Prostate SPORE, InterSPORE Biomarkers Working Group (IPBS)
Invited Pathologist, Prostate Atrophy Consensus Working Group
Laboratory Inspector, College of American Pathologists (CAP) (~5-7 per year).
Ad Hoc Reviewer, NIH Grants Review Panel “Cooperative Human Tissue Network”
RTOG representative, National Group Banking Committee Marketing Subcommittee
Chair, South bay Pathology Society (SBPS) Nominating Committee
Ad Hoc Reviewer, NIH Contracts Review Panel “CTCs Technology”
Grant Reviewer, US Veteran’s Administration Oncology (A) Grant Review Panel
Pathology Cadre Member & Case Reviewer, ALLIANCE (NCI Cooperative Group)
RTOG representative, National Group Banking Committee Regulatory Subcommittee
Grant Reviewer, Prostate Cancer Foundation (PCF), Grant Review Panel
RTOG representative, National Group Banking Committee (GBC)
SUMMARY OF University and Public SERVICE ACTIVITIES
My service involvement stems from my experience and abilities in genitourinary pathology,
Molecular Pathology, and tissue banking. I have become heavily involved in the functioning and
support of the tissue resources in the UCSF Comprehensive Cancer Center and the RTOG (Radiation
Therapy Oncology Group) National Clinical Trials specimen management. This involvement
includes oversight of tissue collection, storage and processing, and quality control measures in order
to ensure that the resource is of highest quality without any compromise to the diagnostic utility of
6
Jeff Simko
these specimens for clinical decision-making. This also involves acting as advisor to, and
collaborator with researchers wanting to use tissue resources in their projects. These interactions
help optimize effective use of the resource by investigators, and also involve aid in study design and
grant proposal preparation. Besides the obvious offshoot into research collaborations and projects,
this experience has also led to my involvement in a number of committees that directly oversee the
management and utilization activities for research tissues, in order to ensure effective collection and
use of these limited resources, which in turn has led to recognition beyond UCSF and involved in
working groups that are trying to standardize diagnostic criteria and tissue collection and storage
protocols across a number of institutions in order to minimize pre-analytical variables that could lead
to confounding results in cross-institutional studies. The ultimate goal of all of this work is to
develop new national standards for tissue collection and processing that will optimize clinical utility
of new biomarkers currently under development. This most recently has lead to, as a member of a
group of pathologists here at UCSF, being awarded the contract to run the RTOG Biospecimen
Resource, one of only eleven NCI funded national cooperative group biospecimen banks.
I also volunteer as a Certified Laboratory Inspector for the College of American Pathology (CAP)
Laboratory Accreditation program, which involves travel to other pathology laboratories in the USA
and around the world (e.g. Japan, Singapore, China, Ireland, United Kingdom) to evaluate their
quality control, assurance and safety procedures. CAP is now planning to expand into certification
processes for Tissue Banks, which will involve similar standards and oversight. I am also helping
UCSF involvement with a delegation from China to develop collaborations in Oncology that will
need pathology support.
Additional service relates to my experience in molecular pathology, where I was involved in
development and planning of a clinical molecular pathology laboratory, and I also served as the
Clinical Proctor for a new Director of the Molecular Pathology Laboratory, as well as now proctoring
new faculty and clinical instructors in Surgical Pathology Case Sign-out.
TEACHING and MENTORING
FORMAL SCHEDULED CLASSES FOR UCSF STUDENTS:
Qtr
Academic
Yr
Course No. & Title
F
2002 - 2003
IDS 102: Organs
F
2002 - 2003
IDS 106: Nutrition and metabolism
F
2003 - 2004
IDS 102: Organs
F
2003 - 2004
IDS 106: Nutrition and metabolism
F-S
2002 - 2003
F-S
2003 – 2004
F
2004 - 2005
Course # 150.03: Surgical
pathology and autopsy pathology
Course # 150.03: Surgical
pathology and autopsy pathology
IDS 106: Nutrition and metabolism
S
2004 - 2005
IDS 102: Organs
S
2004 - 2005
IDS 103: Cancer
Teaching Contribution
Units
Class
Size
Student assistance with Lab teaching
goals
Student assistance with Lab teaching
goals
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Two hour informal lecture to medical
students interested in pathology
Two hour informal lecture to medical
students interested in pathology
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Lab section leader and discussion
leader
4 hrs.
~20
5 hrs.
~20
6 hrs.
~30
5 hrs.
~20
8 hrs.
2-3
8 hrs.
2-3
6 hrs.
~30
4 hrs.
~30
4 hrs.
~20
7
Jeff Simko
F-S
2004 - 2005
Course # 150.03: Surgical &
Autopsy Pathology
IDS 106: Nutrition & Metabolism
F-S
2005-2006
F-S
2005-2006
F
2006
Course # 150.03: Surgical &
Autopsy Pathology
IDS 106: Cancer, bench to bedside
S
2007
IDS 103: Metabolism & Nutrition
F
2007
IDS 106: Cancer, bench to bedside
S
2008
IDS 103: Metabolism & Nutrition
F-S
2007-2008
Course # 150.03: Surgical &
Autopsy Pathology
S
2009
IDS 103: Metabolism & Nutrition
F
2009
IDS 105: Hypersensitivity &Reject
S
2010
IDS 103: Metabolism & Nutrition
F
2010
I3: Hypersensitivity &Rejection
F
2010
M3: Prostate Cancer
S
2011
102B: Organs (renal & urinalysis)
Two hour informal lecture to medical
students interested in pathology
Lab section leader and discussion
leader
Two hour informal lecture to medical
students interested in pathology
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Two hour informal lecture to medical
students interested in pathology
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Lab section leader and discussion
leader
Lab section leader and discussion
leader
8 hrs.
1–3
8 hrs.
~20
8 hrs.
1–3
4 hrs.
~20
4 hrs.
~20
4 hrs.
~20
6 hrs.
~20
6 hrs.
4 hrs.
1-3 /
sessio
n
~20
2 hrs.
~20
8 hrs.
~20
2 hrs.
~ 20
2 hrs.
~ 20
2 hrs.
~ 20
POSTDOCTORAL FELLOWS AND RESIDENTS DIRECTLY SUPERVISED OR MENTORED:
Dates
2003 2006
2004
2005-2006
2007
2007 2010
2008 2010
2010 2011
2010 2012
Name
Status
Faculty Role
Current Position
Jeff Hom, MD
Med Student
Research Supervision
Instructor, Stanford Hospitals
Dean Joelson, MD
Antonio Westphalen,
MD
Javier Rangel, MD
Resident
Clinical Fellow
Clinical Res Supervis
Research Supervision
Research Supervision
John Jalas, M.D.
Medical
Student
Resident
Staff Pathologist, Atlanta, GA
Assoc. Prof in Residence, UCSF
Dept. of Radiology
Staff MD, Redwood Dermatology
Research Supervision
Staff Pathologist, Sant Monica CA
Anobel Odisho
Medical student
Research Supervision
Mike Bonham, MDPhD
Fellow
Samuel Washington
Medical
Student
Clinical and Research
Supervision
Research Supervision
Resident, UCSF Surgery and
Urol.
Director, OUR Labs, Burlingame,
CA
Resident, UCSF Surgery and
Urol.
INFORMAL TEACHING:
RESIDENT TEACHING
2002 – now
Surgical Pathology Case sign-out (the daily review of histology from patient’s surgical
specimens and biopsies with a pathology resident; the core of resident education, 500
hours this year, 600 hours last year)
8
Jeff Simko
2010 – 2012
Director, Urologic Pathology Fellowship Program: Direct, and Mentor a Pathology
Fellow in developing skills specific to the diagnosis of urologic malignancies and other
pathologic processes (240 hours a year).
TEACHING AIDS:
Kidney Tumor Slide Study Set
Bladder Tumor Slide Study Set
Prostate Tumor Slide Study Set
Irradiated Prostate Tumor Slide Study Set
OTHER:
TEACHING PRESENTATIONS AND LECTURES
2000 – 2001
Oncology Fellows’ Core Pathology Education Lecture Series, Dana-Farber Cancer
Institute, Boston: Three lectures on molecular diagnostics for leukemias and lymphomas
2002 – 2003 Basic Pathology Lecture Series, UCSF Department of Urology (Three lectures on basic
pathology of the genitourinary system to Urology Residents: 4 hours per year)
2002 – 2004 Molecular Diagnostic Pathology and Cytogenetics, UCSF Department of Lab Medicine
(Lecture in the core lecture series to residents, 2 hours per year)
2002 – 2005 UCSF Prostate SPORE Working Scientists Meeting (Lecture to Graduate Students, Postdoc’s and junior faculty working on Prostate Cancer Research, 2 hours per year)
2002 – now Genitourinary Clinical Conference Lectures (Lectures to members of the Genitourinary
Oncology Service on Pathology Issues, 2 hours/per year)
2002 – now Urologic Oncology Tumor Board, UCSF Mount Zion Cancer Center, 36
meetings/year
2004 – now Genitourinary Surgical Pathology, Grossing Techniques and Molecular Pathology, UCSF
Department of Anatomic Pathology (9 Lectures in core lecture series to residents, 9 hours
per year)
2004 – now Resident Unknown Slide Conference, UCSF Department of Pathology, 2 hrs./yr.
2004
Current Issues in Anatomic Pathology (UCSF CME Course), San Francisco, CA
2004
UCSF Department of Radiation Oncology Grand Rounds, San Francisco, CA
2005
Current Issues in Anatomic Pathology (UCSF CME Course), San Francisco, CA
2006
Current Issues in Anatomic Pathology (UCSF CME Course), San Francisco, CA
2008
Current Issues in Anatomic Pathology (UCSF CME Course), San Francisco, CA
2008
Pathobiology of Cancer: The Ed Smuckler Memorial Course AACR, Snowmass CO
2009
Pathobiology of Cancer: The Ed Smuckler Memorial Course AACR, Snowmass CO
2010
Current Issues in Anatomic Pathology, San Francisco, CA
2010
American College of Osteopathic Pathology, National Meeting, San Francisco, CA
2011
Guest Professor, Department of Pathology, University of Hawaii Medical School
2012
Current Issues in Anatomic Pathology, San Francisco, CA
2012
RTOG Semiannual Symposium Organizer, Philadelphia (Next Gen Sequencing in
Cooperative group settings)
2013
Current Issues in Anatomic Pathology, San Francisco, CA
2013
Guest Professor, Grand Rounds, Department of Pathology, Harbor-UCLA Medical Ctr.
2013
UCSF Department of Radiation Oncology Grand Rounds, San Francisco, CA
SUMMARY OF TEACHING HOURS:
2003 - 2004:
664 total hours of teaching (not including preparation).
9
Jeff Simko
Formal class, course and lecture teaching hours: 52 hours
Informal teaching hours: 528 hours
Mentoring hours: 84 hours
2004 -2005:
598 total hours of teaching (not including preparation).
Formal class, course and lecture teaching hours: 40 hours
Informal teaching hours: 548 hours
Mentoring hours: 10 hours
2005 – 2006
594 total hours of teaching (not including preparation).
Formal class, course and lecture teaching hours: 30 hours
Informal teaching hours: 544 hours.
Mentoring hours: 20 hours.
2006-2007
604 hours (not including preparation).
Formal class, course and lecture teaching hours: 30 hours
Informal teaching hours: 564 hours
Mentoring hours: 10 hours
2007 - 2008
649 hours (not including preparation).
Formal class, course and lecture teaching hours: 29 hours
Informal teaching hours: 618 hours
Mentoring hours: 2 hours
2008 - 2009
660 hours (not including preparation).
Formal class, course and lecture teaching hours: 29 hours
Informal teaching hours: 629 hours
Mentoring hours: 2 hours
2009 - 2010
620 hours (not including preparation).
Formal class, course and lecture teaching hours: 21 hours
Informal teaching hours: 597 hours
Mentoring hours: 2 hours
2010 - 2011
792 hours (not including preparation).
Formal class, course and lecture teaching hours: 16 hours
Informal teaching hours: 770 hours
Mentoring hours: 6 hours
2011-2012
608 hours (not including preparation).
Formal class, course and lecture teaching hours: 14 hours
Informal teaching hours: 594 hours
Mentoring hours: 2 hours
2012-2013
Total anticipated hours of teaching: 620 hours.
Formal class, course and lecture teaching hours: 20 hours
Informal teaching hours: 600 hours
Mentoring hours: 2 hours
10
Jeff Simko
TEACHING NARRATIVE
My teaching responsibilities at UCSF predominantly involve the one-on-one teaching of the practice
of surgical pathology to residents, fellows and medical students in the Department of Anatomic
Pathology through daily sign out of patients’ surgical specimens (currently 559 hours per year). This
is the backbone of pathology resident education, and involves teaching gross diagnosis, dissection
and tissue handling and preparation, histology and special stain evaluation and interpretation, writing
of microscopic descriptions and pathology reports, communication of findings to clinicians for
optimizing patient care, and frozen section preparation, interpretation and reporting. This effort was
extended to the Urologic Pathology Fellowship that I was in charge of in 2010-2011. This involved
one-on-one instruction of a pathology fellow in the field of urologic pathology and such patient
management (~240 hours), with the graduate (Dr. Mike Bonham) going on to become the Director of
a large regional pathology reference lab. I also give lectures to residents and fellows (Department of
Anatomic Pathology (12 hours per year)) and medical students during their clerkships in the
Department of Anatomic Pathology (~4 hours per year, but none this year), on topics in genitourinary
surgical pathology (prostate pathology, bladder pathology, kidney pathology) and molecular
diagnostic pathology (cytogenetics and related technologies (FISH), and PCR-based testing). I
present pathology to faculty, residents and fellows at the twice-monthly Urologic Oncology Tumor
Board, which involves describing pertinent findings and pathology issues for the cases being
presented, and also discuss developments in surgical pathology practice that may have an impact on
the clinicians’ practices (25 hours per year), as well as directing the bimonthly Urology-Pathology
Case Correlation conference where I present interesting findings and pathology issues to the Urology
fellows and residents that is also useful in their Urology Board Exam preparations (10 hours per
year). I also participate in the pathology sections of the medical student core curriculum and
electives, which involves helping the students to understand and carry out their laboratory
assignments, and giving a small lecture to them at the end of each session in order to summarize the
important points (2 hours per year). I’ve also been an invited speaker every other year for the annual
UCSF Department of Pathology Annual CME course, “Current Issues in Anatomic Pathology,”
where I’ve given lectures to community pathologists on issues regarding genitourinary tumors.
Lastly, I’ve been given responsibility of proctoring new faculty and clinical instructors in the
appropriate handling and reporting of genitourinary Pathology cases at UCSF. This involves review
of all of their cases over the first three months of their service time (~ 30 hours per year). Future
teaching activities will continue along these lines, with plans to expand the number of lectures given
in the core lecture series’ for Anatomic Pathology Residents and Urology Residents, as well as
increased proctoring responsibilities for new faculty and clinical instructors involved in direct patient
care.
RESEARCH AND CREATIVE ACTIVITIES
RESEARCH AWARDS AND GRANTS (last 5 years)
ACTIVE
07/01/10 – 03/01/13
25%
U24 CA114734 (Jordan)
NIH/NCI: Radiation Therapy Oncology Group
RTOG Tissue Bank/Biospecimen Repository: Manage this national cooperative group tissue bank and interact
with the RTOG investigators on collaborative translational research projects.
Role: Co-Investigator (Associate Director)
R01 CA1039434-01A2 (Vigneron)
NIH/NCI
Molecular Imaging of Prostate Cancer
09/01/06 - 02/28/12
$177,500
11
3%
Jeff Simko
The goal of this project is to evaluate the use of new single-shot fast-spin echo diffusion sequence for
improved assessment of prostate cancer extent in patient studies at 1.5T .
Role: Pathology review and direct optimized specimen collection.
R01 CA089715-06A2 (Albertson)
06/01/08-07/31/13
1%
NIH/NCI
$330,371
Bladder Cancer Risk and Genomic Alterations
The goal of this project is to define genomic alterations that are associated with increasing stage of bladder
cancers. Tissue collections with known treatment and follow-up will be used to define prognostic and
predictive utility.
Role: Co-Investigator
R01 (Noworolski)
04/01/10 – 03/31/15
5%
NIH/NCI
$254,940
DCE MRI to Improve Prostate Cancer Identification and Characterization
The goals of this grant are to improve the identification and characterization of aggressiveness of prostate
cancer by utilizing novel pharmacokinetic and statistical models.
Role: Co-investigator
R01 CA137207 (Kurhanewicz)
01/01/11 – 06/30/15
5%
NIH
Translation and Evaluation of a Multi-parametric Prostate Cancer 3T MRI Exam
The overall goal of this academic-industrial partnership is to improve the clinical imaging assessment
of prostate cancer patients by creating a clinically optimized and validated commercial 3T multi-parametric
(T2 MRI, 1H and hyperpolarized 13C MRSI, DTI and DCE) imaging exam for widespread distribution.
Role: Co-Investigator
U01 (Febbo)
5%
NIH
Validation of Prognostic and Predictive Signatures in Lethal Prostate Cancer
The goal is to validate (or not) some of the recently recognized possible biomarkers that help to identify those
tumors that have the highest likelihood of escaping current therapeutic strategies.
Role: Central Pathology review and histologic correlation with molecular findings.
(DOD) Transformative Impact Award (Carroll) 7/1/2013 – 6/30//2016
25%
“Development, Validation, and Dissemination of an Integrated Risk Prediction Model and Decision Aid to
Discern Aggressive Versus Indolent Prostate Cancer”
ROLE: Co-Investigator
PENDING
R01 (Liu)
5%
NIH
Mapping a Clinically Significant Internalizing Tumor Epitope Space
The goal is to develop antibody library-based methods which promote efficient identification of clinically
relevant tumor specific cell surface antigens, methods which are applicable to the identification of cell typespecific lineage markers in general.
Role: Evaluate new antibodies for tissue applications.
DOD (Chan)
5%
12
Jeff Simko
Prostate Microenvironment & Prostate Cancer Progression
The goal is to conduct a novel epidemiologic study of the prostate nutritional microenvironment and its
associations with prostate cancer aggressiveness, gene expression, and genomic copy number in 375 prostate
cancer patients.
Role: Central Pathology review
R01 (Kurhanewicz)
10%
NIH
Hyperpolarized 13C MR - Improved Prostate Cancer Risk Stratification
Radiologic-Pathologic Correlation study to determine if new imaging approach can recognize prostate cancer.
Role: Pathology review and direct optimized specimen collection
R21 (Westphalen)
3%
NIH
Pre-biopsy MR imaging of the prostate in men with elevated PSA
Conventional radiologic pathologic correlation studies of the multiparametric MRI examination.
Role: Central Pathology review
P01 (Lin, Carroll, & Nelson: Simko Tissue Core Co-PI)
10%
NIH
Enhancing Cancer Outcomes in Men: the Prostate Cancer Active Surveillance Study
Evaluate Biomarkers indicative of more indolent forms of prostate cancer with the clinical goal of saving men
from having to undergo unnecessary therapeutic interventions.
Role: Co-PI (Tissue Core Director)
P01 (Knudsen: Simko Tissue Core PI)
5%
Identifying therapeutic targets indicative of enhanced radiation responsiveness in prostate cancer
Evaluate Biomarkers indicative of prostate cancer’s enhanced response to radiation as a primary therapy.
Role: Co-PI (Tissue Core Director)
PAST
RTOG Tissue Bank/Biospecimen Repository (Waldman) 01/01/08 – 06/30/10
30%
Radiation Therapy Oncology Group
RTOG Tissue Bank/Biospecimen Repository: Manage this national cooperative group tissue bank and interact
with the RTOG investigators on collaborative translational research projects.
Role: Co-Investigator (Associate Director)
R01 CA1039434-01A2 (Vigneron)
09/01/06 - 02/28/11
5%
NIH/NCI
$177,500
Based Molecular Imaging of Prostate Cancer
The goal of this project is to evaluate the use of new single-shot fast-spin echo diffusion sequence for
improved assessment of prostate cancer extent in patient studies at 1.5T.
Role: Pathology review and direct optimized specimen collection.
R01 CA118919 (Liu)
03/01/06-02/28/11
NIH
$250,000
Mapping a Clinically Significant Internalizing Tumor Epitope Space
13
4%
Jeff Simko
The goal is to develop antibody library-based methods which promote efficient identification of clinically
relevant tumor specific cell surface antigens, methods which are applicable to the identification of cell typespecific lineage markers in general.
Role: Evaluate new antibodies for tissue applications.
RO1 CA106947-01A2 (Chan)
05/01/07 – 08/31/10
5%
NIH
$279.000
Prostate Microenvironment & Prostate Cancer Progression
The goal is to conduct a novel epidemiologic study of the prostate nutritional microenvironment and its
associations with prostate cancer aggressiveness, gene expression, and genomic copy number in 375 prostate
cancer patients.
Role: Central Pathology review
NIH (Waldman)
04/01/08-03/31/10
5%
NIH
$1,932,304
Predictive Markers in Metastatic Renal Cancer
The goals of this project are understand the biological mechanisms underlying the risk factors for kidney and
bladder cancer phenotypes and identify global genetic, epigenetic, RNA expression, and proteomic alterations
in tumors and place them in specific biological pathways that are essential to development, progression,
response to therapy, and maintenance of subtypes of bladder and kidney cancers.
Role: Co-investigator (Central Pathology review and histologic correlation with molecular findings).
R01 CA102751 (Kurhanewicz)
03/01/05 – 08/31/06
5%
NIH/NCI
$294,530
MR Based Molecular Imaging of Prostate Cancer
The goal of this project is to correlate pathologic findings, expression profiles and genetic changes to
spectroscopic (chemical) findings determined by Magnetic Resonance Spectroscopic Imaging (MRSI).
Role: Pathology review and direct optimized specimen collection
R01 CA101042 (Haqq)
06/10/03-05/31/08
5%
NIH/NCI
$225,500
Molecular Effects of Nutrition Supplements in Prostate Trials
Clinical trial of using microarrays to discover the transcriptome response to diet for prostate cancer.
Role: Pathology review and direct optimized specimen collection
R01 CA102600 (Waldman)
08/01/03-05/31/08
10%
NIH/NCI
$15,977
Renal Cancer Genomic Alterations and Environmental Risk
The overall design of this study is to characterize over 700 renal tumors by array CGH to define genomic
alterations and their associations with clinical variables, and with exposure, and genetic risk factors
Role: Co-investigator (Central Pathology review and histologic correlation with molecular findings).
Mount Zion Health Fund (Simko)
UCSF Comprehensive Cancer Center
Magnetic Resonance Profiles (NMR) of Renal Tumors
Role: PI
01/01/07 – 02/28/09
$15,000
NIH (Coakley)
04/01/04-03/31/09
1%
NIH/NCI
$91,000
ACRIN 6659: MR Imaging and MR Spectroscopic Imaging of Prostate Cancer Prior to Radical
Prostatectomy: A Prospective Multi-Institutional Clinicopathological Study. The goal of this project is to
compare the diagnostic accuracy of MRI alone compared to MRI combined with MRSI for the localization of
prostate cancer in patients who are scheduled to have radical prostatectomy surgery.
14
Jeff Simko
Role: Pathology review and direct optimized specimen collection
ACS (Noworolski)
01/01/05 - 12/31/09
5%
American Cancer Society
$117,099
“Dynamic Contrast-Enhanced MRI of Prostate Cancer.” Acquisition and post-processing of dynamic contrastenhanced MRI (DCE MRI) of prostate will be developed and compared to MRI, MR spectroscopic imaging
(MRSI) and histopathological analysis of prostate tissue to determine possible value for clinical applications.
Role: Pathology review and direct optimized specimen collection
RSG-05-241-01-CCE (Swanson)
07/01/05-06/30/09
5%
American Cancer Society
$149,491
Metabolic Profiles of Residual/Recurrent Prostate Cancer After Therapy
The goal of this project is to determine whether the levels of specific choline and ethanolamine containing
compounds correlate with the presence of residual or recurrent prostate cancer following hormone deprivation
and radiation therapies.
Role: Pathology review and direct optimized specimen collection
P50 CA89520 (Shuman)
07/01/08-06/30/09
10%
NIH/NCI – Bridge Funding
$21,537
Prostate SPORE-Core B: Tissue Core (PI: Simko, Jeffry)
Project 4: Antibody Gene Diversity Libraries and Phage Display to Generate Recombinant Human Antibodies
for Prostate Cancer Therapy
The major goals are to 1) generate new phage antibody libraries; 2) select antibodies which bind specifically to
prostate cancer cells; and 3) use the antibodies to isolate novel prostate cancer surface antigens.
Role: Co-PI (Tissue Core Director)
P50 CA89520 (Shuman)
10/01/00-06/30/06
55%
NIH/NCI
Prostate SPORE-Core B: Tissue Core (PI: Simko, Jeffry)
Project 4: Antibody Gene Diversity Libraries and Phage Display to Generate Recombinant Human Antibodies
for Prostate Cancer Therapy
The major goals are to 1) generate new phage antibody libraries; 2) select antibodies which bind specifically to
prostate cancer cells; and 3) use the antibodies to isolate novel prostate cancer surface antigengs.
Role: Co-PI (Tissue Core Director)
15
Jeff Simko
PEER REVIEWED PUBLICATIONS:
1. J.P. Simko and G Oehrlein, "Reactive Ion Etching of Silicon and Silicon Dioxide in CF4 Plasmas
containing Hydrogen or C2F4 additives", J. of the Electrochemical Society 138, 2748 (1991).
2. J.P. Simko, G.S. Oehrlein and T.M. Mayer, "Removal of Fluorocarbon Residues on CF4/H2
Reactive Ion Etched Silicon Surfaces using a Hydrogen Plasma", J. of the Electrochemical
Society 138, 277 (1991).
3. Y.Z. Hu, K.A. Conrad, M. Li, J.W. Andrews, J.P. Simko and E.A. Irene, "Studies of Hydrogen Ion
Beam Cleaning of Silicon Dioxide from Silicon using in-situ Spectroscopic Ellipsometry and X-ray
Photo-electron Spectroscopy", Applied Physics Letters 58, 589 (1991).
4. J.P. Simko, T. Meguro, S. Iwai, K. Ozasa, A. Hirata, Y. Aoyagi and T. Sugano, "Direct
Observation of Self-limiting Gallium Deposition on Gallium Arsenide during Laser-atomic Layer
Epitaxial Processing", Japan Journal of Applied Physics Letters 39, L1518 (1992).
5. J.P. Simko, T. Meguro, S. Iwai, K. Ozasa, Y. Aoyagi and T. Sugano, "Surface Photo-absorption
Study of the Laser-assisted Atomic Layer Epitaxial Growth Process of Gallium Arsenide",
Proceedings of the Second International Symposium on Atomic Layer Epitaxy, June 3-6, 1992,
Raleigh, North Carolina, Thin Solid Films 225, 40 (1993).
6. J.P. Simko, A. Caliendo, K. Hogle, J. Versalovic, “Detection of Herpes Simplex Virus DNA in
Cerebrospinal Fluid specimens by PCR: Correlation with Clinical Presentation and Patient
History,” Clin. Infect. Dis. 35(4): 414-9 (2002).
7. Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, Brebner JH, Simko J, Watson
JE, Volik S, Albertson DG, Pinkel D, Alers JC, van der Kwast TH, Vissers KJ, Schroder FH,
Wildhagen MF, Febbo PG, Chinnaiyan AM, Pienta KJ, Carroll PR, Rubin MA, Collins C, van
Dekken H., "Whole genome scanning identifies genotypes associated with recurrence and
metastasis in prostate tumors," Hum Mol Genet. 13(13): 1303-13 (2004).
8. Watson JE, Doggett NA, Albertson DG, Andaya A, Chinnaiyan A, Van Dekken H, Ginzinger D,
Haqq C, James K, Kamkar S, Kowbel D, Pinkel D, Schmitt L, Simko JP, Volik S, Weinberg VK,
Paris PL, Collins C., “Integration of high-resolution array comparative genomic hybridization
analysis of chromosome 16q with expression array data refines common regions of loss at 16q23qter and identifies underlying candidate tumor suppressor genes in prostate cancer. Oncogene
23(19):3487-94 (2004).
9. Watson JE, Kamkar S, James K, Kowbel D, Andaya A, Paris PL, Simko J, Carroll P, McAlhany S,
Rowley D, Collins C, "Molecular analysis of WFDC1/ps20 gene in prostate cancer," Prostate
61(2): 192-9 (2004).
10. Retz MM, Sidhu SS, Blaveri E, Kerr SC, Dolganov GM, Lehmann J, Carroll P, Simko J,
Waldman FM, Basbaum C, "CXCR4 expression reflects tumor progression and
regulates motility of bladder cancer cells," Int J Cancer 114(2): 182-9 (2005).
16
Jeff Simko
11. E Blaveri, JP Simko, JE Korkola, JL Brewer, F Baehner, K Mehta, S DeVries, T Koppie, S
Pejavar, P Carroll and F Waldman, "GENE EXPRESSION PATTERNS IDENTIFY BLADDER
CANCER SUBTYPES AND PREDICT OUTCOME," Clin Cancer Res 11(11): 4044-55 (2005).
12. Master VA, Chi T, Simko JP, Weinberg V, Carroll PR, "The independent impact of extended
pattern biopsy on prostate cancer stage migration," J Urol 174(5): 1789-93 (2005).
13. Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T, Pejavar S, Mehta K,
Carroll P, Simko JP, Waldman FM, "Bladder cancer stage and outcome by array-based
comparative genomic hybridization," Clin Cancer Res 11(19 Pt 1): 7012-22 (2005).
14. WA Ricke, K Ishii, EA Ricke, JP Simko, YZ Wang, SW Hayward, and FR Cunha, "Steroid
Hormones Stimulate Human Prostate Cancer Progression and Metastasis,” Int J Cancer 118(9):
2123-31 (2006).
15. Paris P, Weinberg V, Simko J, Andaya A, Albo G, Rubin M, Carroll P, Collins C, "Preliminary
Validation of Prostate Cancer Metastatic Risk Biomarkers," Int. J. Biomarkers 20(3): 141-45
(2005).
16. Hom JJ, Coakley FV, Simko JP, Qayyum A, Lu Y, Schmitt L, Carroll PR, Kurhanewicz J,
"Prostate Cancer: Endorectal MR Imaging and MR Spectroscopic Imaging--Distinction of TruePositive Results from Chance-detected Lesions," Radiology 238(1): 192-9 (2006).
17. Rini BI, Weinberg V, Dunlap S, Elchinoff A, Yu N, Bok R, Simko J, Small EJ, "Maximal COX-2
immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal
cell carcinoma," Cancer 106(3): 566-75 (2006).
18. Sanchez-Mejia RO, Ojemann SG, Simko J, Chaudhary UB, Levy J, Lawton MT, "Sacral
epithelioid angiosarcoma associated with a bleeding diathesis and spinal epidural hematoma: case
report," J Neurosurg Spine 4(3): 246-50 (2006).
19. A M De Marzo , E A Platz , J I Epstein , T Ali , A Billis, T Y Chan , L Cheng, M Datta, L Egevad,
D Ertoy-Baydar , X Farre , S W Fine , K A Iczkowski, M Ittmann, B S Knudsen, M Loda, A
Lopez-Beltran, C Magi-Galluzzi, G Mikuz , R Montironi, E Pikarsky, G Pizov, M A Rubin, H
Samaratunga, T Sebo, I A Sesterhenn, RB Shah, S Signoretti, J Simko ,G Thomas, P Troncoso, T
Tsuzuki, G JLH van Leenders, XJ Yang, M Zhou, W D Figg, A Hoque and M S Lucia, "A
Working Group Classification of Focal Prostate Atrophy Lesions," Am. J. Surg. Pathol. 30(10):
1281-91 (2006).
20. M Swanson, A Zektzer, ZL Tabatabai, J Simko, S Jarso, K Keshari, L Schmitt, P Carroll, K
Shinohara, D Vigneron, and J Kurhanewicz, "Quantitative Analysis of Prostate Metabolites using
1H HR-MAS Spectroscopy," Mag Res Med 55(6): 1257-64 (2006).
21. B. Rini, E. Jaeger, N. Sein, K. Fong, K. Chew, J. Simko and F. Waldman, “Clinical Response to
VEGF-Targeted Therapy in Metastatic Renal Cell Carcinoma: Impact of Patient Characteristics
and VHL Gene Status,” Br. J. Urol. Int. 98(4): 756-62 (2006).
17
Jeff Simko
22. Ruan W, Sassoon A, An F, Simko JP, Liu B, "Identification of clinically significant tumor
antigens by selecting phage antibody library on tumor cells in situ using laser capture
microdissection," Mol Cell Proteomics 5(12) 2364-73 (2006).
23. PL Paris, MD Hofer, G Albo, R Kuefer, JE Gschwend, RE Hautmann, J Fridyland, JP Simko, PR
Carroll, MA Rubin, and C Collins,”Genomic profiling of hormone naïve lymph node metastases in
patients with prostate cancer," Neoplasia 8(12): 1083-9 (2006).
24. Ryan C, Haqq C, Simko J, Chan J, Weinberg V, Goldfine I, “Expression of insulin-like growth
factor 1 receptor in local and metastatic prostate cancer,” Uro. Oncol 25(2): 134-40 (2007).
25. Hom JJ, Coakley FV, Simko JP, Lu Y, Qayyum A, Westphalen A, Schmitt L, Carroll PR,
Kurhanewicz J. “High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR
and MR spectroscopic imaging features,” Radiology 242(2): 483-9 (2007).
26. W. Nau, E. Bass, C. Diederich, W. Ferrier, J. Simko, R. Pelligrino, J. Sutton and R. Shu,
“Intradiscal thermal Therapy Using Interstitial Unltrasound: An In Vivo Feasibility Study in Ovine
Cervical Spine,” Spine 32(5): 503-11 (2007).
27. Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins
C, Bismar TA, Chinnaiyan AM, Rubin MA, "Morphological features of TMPRSS2-ERG gene
fusion prostate cancer," J Pathol 212(1): 91-101 (2007).
28. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA,
Chinnaiyan AM, De Marzo AM, Rubin MA, "TMPRSS2-ERG Fusion Prostate Cancer: An Early
Molecular Event Associated With Invasion," Am J Surg Pathol 31(6): 882-888 (2007).
29. Jancelewicz T, Simko J, Lee H, "Obstructing ileal duplication cyst infected with Salmonella in a
2-year-old boy: a case report and review of the literature," J Pediatr Surg 42(5): E19-21 (2007).
30. Liu B, Conrad F, Roth A, Drummond DC, Simko JP, Marks JD, "Recombinant full-length human
IgG1s targeting hormone-refractory prostate cancer," J Mol Med 85(10): 1113-23 (2007).
31. Westphalen AC, Coakley FV, Qayyum A, Swanson M, Simko JP, Lu Y, Zhao S, Carroll PR, Yeh
BM, Kurhanewicz J, "Peripheral zone prostate cancer: accuracy of different interpretative
approaches with MR and MR spectroscopic imaging," Radiology 246(1): 177-84 (2008).
32. D. Ornish, M Magbanua, G Weidner, V Weinberg, C Kemp, C Green, M Mattie, R Marlin, J
Simko, K Shinohara, C Haqq and P Carroll, "Changes in prostate Gene expresssion in men
undergoing an intensive nutrition and lifestyle intervention," PNAS 105(24): 8369-74 (2008).
33. Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K, Carroll PR, Zektzer AS,
Kurhanewicz J, "Quantification of choline- and ethanolamine-containing metabolites in human
prostate tissues using 1H HR-MAS total correlation spectroscopy," Magn Reson Med 60(1): 33-40
(2008).
34. Mosquera JM, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, Paris PL, Simko J, Bismar
TA, Ayala G, Shah RB, Loda M, Rubin MA, "Characterization of TMPRSS2-ERG fusion high18
Jeff Simko
grade prostatic intraepithelial neoplasia and potential clinical implications," Clin Cancer Res
14(11): 3380-5 (2008).
35. Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N,
Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R,
"von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy
for metastatic clear cell renal cell carcinoma," J Urol 180(3): 860-5 (2008).
36. Tessem MB, Swanson MG, Keshari KR, Albers MJ, Joun D, Tabatabai ZL, Simko JP, Shinohara
K, Nelson SJ, Vigneron DB, Gribbestad IS, Kurhanewicz J, "Evaluation of lactate and alanine as
metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues," Magn
Reson Med 60(3): 510-6 (2008).
37. Paris PL, Sridharan S, Hittelman AB, Kobayashi Y, Perner S, Huang G, Simko J, Carroll P,
Rubin MA, Collins C, "An oncogenic role for the multiple endocrine neoplasia type 1 gene in
prostate cancer," Prostate Cancer Prostatic Dis. 12(2): 184-91 (2009).
38. C Crane, A Panner, JC Murray, SP Wilson, H Xu, L Chen, JP Simko, FM Waldman, RO Pieper
and AT Parsa, "P(i)3 kinase is associated wit a mechanism of immunoresistance in breast and
prostate cancer," Oncogene 28(2): 306-12 (2009).
39. Paris PL, Kobayashi Y, Zhao Q, Zeng W, Sridharan S, Fan T, Adler HL, Yera ER, Zarrabi MH,
Zucker S, Simko J, Chen WT, Rosenberg J, "Functional phenotyping and genotyping of
circulating tumor cells from patients with castration resistant prostate cancer," Cancer Lett 277(2):
164-73 (2009).
40. Torabian SZ, de Semir D, Nosrati M, Bagheri S, Dar AA, Fong S, Liu Y, Federman S, Simko J,
Haqq C, Debs RJ, Kashani-Sabet M, "Ribozyme-mediated targeting of IkappaBgamma inhibits
melanoma invasion and metastasis," Am J Pathol 174(3): 1009-16 (2009).
41. Conti SL, Dall'era M, Fradet V, Cowan JE, Simko J, Carroll PR, "Pathological outcomes of
candidates for active surveillance of prostate cancer," J Urol 181(4): 1628-33 (2009).
42. Kashani-Sabet M, Rangel J, Torabian S, Nosrati M, Simko J, Jablons DM, Moore DH, Haqq C,
Miller JR 3rd, Sagebiel RW, "A multi-marker assay to distinguish malignant melanomas from
benign nevi," Proc Natl Acad Sci U S A. 106(15): 6268-72 (2009).
43. Hou Y, DeVoss J, Dao V, Kwek S, Simko JP, McNeel DG, Anderson MS, Fong L, "An aberrant
prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic
prostatitis in humans," J Clin Invest 119(7): 2031-41 (2009).
44. Westphalen AC, Coakley FV, Kurhanewicz J, Reed G, Wang ZJ, Simko JP, "Mucinous
adenocarcinoma of the prostate: MRI and MR spectroscopy features," Am J Roentgenol 193(3):
W238-43 (2009).
45. Kashani-Sabet M, Venna S, Nosrati M, Rangel J, Sucker A, Egberts F, Baehner FL, Simko J,
Leong SP, Haqq C, Hauschild A, Schadendorf D, Miller JR 3rd, Sagebiel RW, "A multimarker
prognostic assay for primary cutaneous melanoma," Clin Cancer Res 15(22): 6987-92 (2009).
19
Jeff Simko
46. Paris PL, Weinberg V, Albo G, Roy R, Burke C, Simko J, Carroll P, Collins C, "A group of
genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with
high-risk prostate cancer," Clin Cancer Res 16(1): 195-202 (2010).
47. Santos CF, Kurhanewicz J, Tabatabai ZL, Simko JP, Keshari KR, Gbegnon A, Santos RD,
Federman S, Shinohara K, Carroll PR, Haqq CM, Swanson MG, "Metabolic, pathologic, and
genetic analysis of prostate tissues: quantitative evaluation of histopathologic and mRNA integrity
after HR-MAS spectroscopy," NMR Biomed 23(4): 391-8 (2010).
48. Vagefi PA, Klein I, Gelb B, Hameed B, Moff SL, Simko JP, Fix OK, Eilers H, Feiner JR, Ascher
NL, Freise CE, Bass NM, "Emergent Orthotopic Liver Transplantation for Hemorrhage from a Giant
Cavernous Hepatic Hemangioma: Case Report and Review," J Gastrointest Surg 15(1): 209-14
(2011).
49. Dall'era MA, Cowan JE, Simko J, Shinohara K, Davies B, Konety BR, Meng MV, Perez N, Greene
K, Carroll PR, "Surgical management after active surveillance for low-risk prostate cancer:
pathological outcomes compared with men undergoing immediate treatment," BJU Int 107(8): 12327 (2011).
50. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stöppler H, Simko J, Hilton JF, Carroll P,
Blelloch R, "Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic
microRNA signatures in the sera of prostate cancer patients," Cancer Res 71(2): 550-60 (2011).
51. Chan JM, Weinberg V, Magbanua MJ, Sosa E, Simko J, Shinohara K, Federman S, Mattie M,
Hughes-Fulford M, Haqq C, Carroll PR, "Nutritional supplements, COX-2 and IGF-1 expression in
men on active surveillance for prostate cancer," Cancer Causes Control 22(1): 141-50 (2011).
52. Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV,
Simko JP, Shinohara K, Carroll PR, "The relationship between prostate specific antigen change
and biopsy progression in patients on active surveillance for prostate cancer," J Urol 185(5): 165660 (2011).
53. Whitson JM, Porten SP, Cowan JE, Simko JP, Cooperberg MR, Carroll PR, "Factors associated
with downgrading in patients with high grade prostate cancer," Urol Oncol. 2011 Apr 7. [Epub
ahead of print]
54. McKenney JK, Simko J, Bonham M, True LD, Troyer D, Hawley S, Newcomb LF, Fazli L, Kunju
LP, Nicolas MM, Vakar-Lopez F, Zhang X, Carroll PR, Brooks JD; Canary/Early Detection
Research Network Prostate Active Surveillance Study Investigators, "The potential impact of
reproducibility of Gleason grading in men with early stage prostate cancer managed by active
surveillance: a multi-institutional study," J Urol 186(2): 465-9 (2011).
55. Jalas JR, Vemula S, Bezrookove V, Leboit PE, Simko JP, Bastian BC, "Metastatic melanoma with
striking adenocarcinomatous differentiation illustrating phenotypic plasticity in melanoma," Am J
Surg Pathol 35(9): 1413-8 (2011).
56. Magbanua MJ, Roy R, Sosa EV, Weinberg V, Federman S, Mattie MD, Hughes-Fulford M, Simko
J, Shinohara K, Haqq CM, Carroll PR, Chan JM, "Gene expression and biological pathways in tissue
20
Jeff Simko
of men with prostate cancer in a randomized clinical trial of lycopene and fish oil supplementation,"
PLoS One. 2011;6(9):e24004. Epub 2011 Sep 1.
57. Ray M, Hostetter DR, Loeb CR, Simko J, Craik CS, "Inhibition of Granzyme B by PI-9 protects
prostate cancer cells from apoptosis," Prostate. 2012 Jun 1;72(8):846-55. doi: 10.1002/pros.21486.
Epub 2011 Sep 14.
58. Chen L, Hong C, Chen EC, Yee SW, Xu L, Almof EU, Wen C, Fujii K, Johns SJ, Stryke D, Ferrin
TE, Simko J, Chen X, Costello JF, Giacomini KM, "Genetic and epigenetic regulation of the organic
cation transporter 3, SLC22A3," Pharmacogenomics J. 2012 Jan 10. doi: 10.1038/tpj.2011.60. [Epub
ahead of print]
59. Magbanua MJ, Sosa EV, Scott JH, Simko J, Collins C, Pinkel D, Ryan CJ, Park JW, "Isolation and
genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer,"
BMC Cancer. 2012 Feb 28;12(1):78. [Epub ahead of print]
60. Busch S, Hatridge M, Mößle M, Myers W, Wong T, Mück M, Chew K, Kuchinsky K, Simko J,
Clarke J, "Measurements of T(1) -relaxation in ex vivo prostate tissue at 132 μT," Magn Reson Med.
2012 Apr;67(4):1138-45. doi: 10.1002/mrm.24177. Epub 2012 Jan 31.
61. Ausborn NL, Le QT, Bradley JD, Choy H, Dicker AP, Saha D, Simko J, Story MD, Torossian A, Lu
B, "Molecular Profiling to Optimize Treatment in Non-Small Cell Lung Cancer: A Review of
Potential Molecular Targets for Radiation Therapy by the Translational Research Program of the
Radiation Therapy Oncology Group," Int J Radiat Oncol Biol Phys. 2012 Apr 18. [Epub ahead of
print]
62. Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI, "Do Adenocarcinomas of
the Prostate With Gleason Score (GS)≤6 Have the Potential to Metastasize to Lymph Nodes?," Am J
Surg Pathol. 2012 Apr 22. [Epub ahead of print]
63. Hayes GM, Simko J, Holochwost D, Kuchinsky K, Busch R, Misell L, Murphy EJ, Carroll PR,
Chan JM, Shinohara K, Hellerstein MK, "Regional Cell Proliferation in Microdissected Human
Prostate Specimens After Heavy Water-Labeling in vivo: Correlation With Prostate Epithelial Cells
Isolated From Seminal Fluid," Clin Cancer Res. 2012 May 2. [Epub ahead of print]
64. Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, Small EJ, Fong L, "Diversity of antigenspecific responses induced in vivo with ctla-4 blockade in prostate cancer patients, J Immunol
189(7): 3759-66 (2012).
65. Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, Gutin A, Lanchbury JS,
Swanson GP, Stone S, Carroll PR, "Validation of a cell-cycle progression gene panel to improve risk
stratification in a contemporary prostatectomy cohort," J Clin Oncol 31(11): 1428-34 (2013).
66. Hawley S, Fazli L, McKenney JK, Simko J, Troyer D, Nicolas M, Newcomb LF, Cowan JE, Crouch
L, Ferrari M, Hernandez J, Hurtado-Coll A, Kuchinsky K, Liew J, Mendez-Meza R, Smith E,
Tenggara I, Zhang X, Carroll PR, Chan JM, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM,
Feng Z, True LD, Brooks JD, "A model for the design and construction of a resource for the
21
Jeff Simko
validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray,"
Adv Anat Pathol 20(1): 39-44 (2013).
67. Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK,
Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS, "Incomplete inhibition of
phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR
inhibitors," Oncogene. 2013 Apr 1. doi: 10.1038/onc.2013.92. [Epub ahead of print]
68. Odisho AY, Washington SL 3rd, Meng MV, Cowan JE, Simko JP, Carroll PR, "Benign Prostate
Glandular Tissue at Radical Prostatectomy Surgical Margins," Urology 82(1) 154-9 (2013).
69. Stieglitz E, Hsiang MS, Simko JP, Hirose S, Goldsby RE, "Pulmonary Coccidiomycosis
Masquerading as Refractory Metastatic Ewing Sarcoma," J Pediatr Hematol Oncol 36(1): E57-60
(2014).
70. O Starobinets, R Guo, JP Simko, MD, PhD, K Kuchinsky, J Kurhanewicz, PR Carroll, KL Greene,
SM Noworolski, "Semi-automatic registration of digital histopathology images to in-vivo MR images
in molded and unmolded prostates," Accepted, JMRI 2013
71. Van Allen EM, Foye A, Wagle N, Kim W, Carter SL, McKenna A, Simko JP, Garraway LA, Febbo
PG, "Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy," Prostate
Cancer Prostatic Dis. 2013 Dec 24. doi: 10.1038/pcan.2013.37. [Epub ahead of print] PMID:
24366412
72. Anwar M, Coakley F, Roach M, Westphalen AC, Jung A, Noworolski S, Simko J, Kurhanewicz J,
Carroll P, "Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable
intraprostatic tumor foci in prostate cancer: Quantitative analysis of imaging contour compared to
whole-mount histopathology," Submitted, Int J Rad Oncol
73. H. Dean Hosgood, William Pao, Nathaniel Rothman, Hu Wei, Yumei Helen Pan, Kyle Kuchinsky,
Kirk Jones, Jun Xu, Roel Vermeulen, Jeffry Simko, Qing Lan, "Driver mutations among never
smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern
associated with household coal burning," Respir Med 107(11) 1755-62 (2013).
74. MJM Magbanua, EL Richman, EV Sosa, LW Jones, JP Simko, KShinohara, CM Haqq, PR Carroll,
JM Chan,"Physical activity and prostate gene expression in men with low risk prostate cancer,"
Submitted, PLos One
75. MR Cooperberg, JE Cowan, JP Simko, T Maddala, JM Chan, AC Tsiatis, I Tenggara-Hunter, D
Knezevic, FL Baehner, S Shak, M Lee, and PR Carroll, "Validation of a biopsy-based multi-gene
predictor of adverse prostate cancer pathology to improve patient selection for active surveillance,"
Submitted NEJM
NON-PEER REVIEWED PUBLICATIONS AND OTHER CREATIVE ACTIVITIES:
1. S.J. DeArmond, J.P. Simko and D.A. Gaskin, “The Molecular and Genetic Basis of
Neurodegenerative Diseases,” in Modern Surgical Pathology, N. Weidner, Ed. (W.B. Saunders, New
York, 2003) pp. 2121-2153.
22
Jeff Simko
2. JP Simko and FM Waldman, “Molecular and Special Techniques,” in Immunomicroscopy: A
Diagnostic Tool for the Surgical Pathologist, 3rd Edition, C. Taylor, R. Cote Eds. (Elsevier, St. Louis,
2006).
3. JP Simko, Editorial for H. Eyas, et al., “Tertiary Gleason Pattern 5 is a Powerful Predictor of
Biochemical Relapse in Patients with Gleason Score 7 Prostatic Adenocarcinoma,” J. Urol. (2006).
4. BM Ljung and JP Simko, “Issues and Methodologies for Sampling Breast Cancers for Molecular
Studies and Diagnosis: Lessons from a Pathologist’s Bench,” in Seminars in Breast Disease, A.
Thor Ed. (Elsevier, St. Louis, 2007).
5. S.J. DeArmond, TA Tousseyn, J.P. Simko and D.A. Gaskin, “The Molecular and Genetic Basis of
Neurodegenerative Diseases” in Modern Surgical Pathology Second Edition, N. Weidner, Ed. (W.B.
Saunders, New York, 2009) pp. 2039-2068.
6. Simko JP, "Letter to the editor," J Urol 190(6): 2066-7 (2013).
23
Jeff Simko
RESEARCH PROGRAM
My major research interests at this time generally involve improving physicians’ diagnostic
capabilities for the management of patients with genitourinary malignancies. These activities are
focused in two areas of diagnostic medicine; radiologic-pathologic correlation studies, and
elucidation of diagnostic and prognostic biomarkers in GU malignancies. These activities are
predominantly undertaken within the UCSF Comprehensive Cancer Center Genitourinary Oncology
Program, the former UCSF Prostate SPORE program, the Canary Foundation Program, the RTOG
clinical trials cooperative group, and THE ALLIANCE (former CALGB) clinical trials cooperative
group; all of which are multidisciplinary teams of collaborative researchers with the common goal of
improving the management of patients with genitourinary malignancies (prostate cancer, bladder
cancer and kidney cancer). My primary responsibility in these groups is to provide the pathology
support for these efforts, including overseeing collection, processing and distribution of appropriate
tissue samples and pathologic specimens to the research projects, consultation and planning of
experiments and grant proposals for most effective use and financing of tissue and pathology
resources, and ultimately use and interpretation of histologic, immunohistologic and in-situ
hybridization tissue sections within the projects themselves. Resident and medical student
involvement is encouraged and has occurred.
Radiologic-pathologic correlation studies: UCSF is in a very unique and enviable position due to the
vast magnetic resonance imaging resources here in the Department of Radiology. A number of studies
are underway to evaluate and interpret signals from nuclear magnetic resonance techniques (NMR /
MRI), including magnetic resonance spectroscopic imaging (MRSI), and the new Hyperpolarized
Carbon-13 NMR system that enhances the signal of carbon nuclei 50,000-fold. Use of these techniques
for the diagnosis of prostate cancer is currently limited by poor sensitivity and specificity, due to a lack of
understanding of the types of signals generated from specific tissue types. In our most recent work, we
feel that we’ve identified some tissue types that mimic the MRI signals produced by prostate cancer.
Other studies involve correlation of MRSI signals with histologic, immunohistochemical, expression and
genomic findings and patient outcome, in order to determine the relationship of tumor chemical
composition to virulence and metastatic capability. Moving forward, we hope to extend this
understanding to Carbon-13-based imaging, as well as imaging of renal tumors. I’ve also extended
collaboration to the UC Berkeley Physics Department to evaluate the potential of alternative magnetic
imaging techniques for cancer detection using SQUID magnetometers.
Biomarkers: My other focus is within the realm of histologic, genetic and protein expression
alterations within various genitourinary malignancies, with the major goal being to better
characterize tumors for improved diagnostic and prognostic purposes, and also identifying new
avenues for potential therapeutic strategies. Projects underway include histologic evaluation of
prostate and renal tumors for national clinical trials (Canary Foundation, RTOG, ALLIANCE and
industrial partners) to correlate with response to therapy, outcomes, and putative biomarkers. Related
to these efforts are attempts to enhance biospecimen collection and evaluation of biomarker stability
and specimen utility for these trials. This extends to efforts to collect circulating tumor cells and
matching primary tumor tissue specimens, as well as other important tumor types ( pancreas and lung
carcinomas), where I constructed TMAs of tissues collected from RTOG clinical trials and cohort
studies through the NCI Division of Cancer Epidemiology and Genetics. Future plans include
participation in the cancer genome atlas (TCGA) project of NCI, and increased efforts within RTOG
as it merges with other Clinical trials groups during the NCI-mandated consolidation of these entities
(merger with Gynecologic Oncology Group (GOG) and the National Surgical Adjuvant Breast and
Bowel Project (NSABP)).
24
Jeff Simko
Listing of most significant recent publications in last two years:
1.Jalas JR, Vemula S, Bezrookove V, Leboit PE, Simko JP, Bastian BC, "Metastatic melanoma with
striking adenocarcinomatous differentiation illustrating phenotypic plasticity in melanoma," Am J Surg
Pathol 35(9): 1413-8 (2011). In this patient case, I recognized an unusual growth pattern in a metastatic
melanoma that turned out to be a carcinoma. I was then able to have my dermatopathology colleagues
determine whether this was indeed the same tumor or a different tumor via molecular testing. This
turned out to be the first report of carcinomatous differentiation demonstrated by a melanoma, adding
further credence to the overarching concept of tumor plasticity and epithelial-mesenchymal transitions.
2. Paris PL, Kobayashi Y, Zhao Q, Zeng W, Sridharan S, Fan T, Adler HL, Yera ER, Zarrabi MH,
Zucker S, Simko J, Chen WT, Rosenberg J, "Functional phenotyping and genotyping of circulating
tumor cells from patients with castration resistant prostate cancer," Cancer Lett 277(2): 164-73 (2009).
This is the first report of a genome-wide evaluation of circulating tumor cells (CTCs); an extremely
significant feat, as only a handful of CTCs are ever recoverable from patient blood (< 100 cells). Such
analyses will hopefully lead to a clearer understanding of the development of metastatic tumor capability.
For this study, I was responsible for developing a collaboration with the inventor of a new CTC isolation
technology, Dr. WT Chen of SUNY Stony Brook, and I then helped assemble the appropriate team to
perform these unique measurements, as well as help get Dr. Paris and others at UCSF (Dr. M.
Magbanua), interested in this new area of research, and more data being generated.
3. Busch S, Hatridge M, Mößle M, Myers W, Wong T, Mück M, Chew K, Kuchinsky K, Simko J,
Clarke J, "Measurements of T(1) -relaxation in ex vivo prostate tissue at 132 μT," Magn Reson Med.
2012 Apr;67(4):1138-45. doi: 10.1002/mrm.24177. Epub 2012 Jan 31.
Useful imaging for evaluation of the prostate are seriously lacking. This report provides first evidence of
a radical departure from the current thinking in MRI science that higher magnetic fields create more
resolution (smaller features). While such is true, it does not consider the reduced contrast between tissue
types (lack of differentiating signal) at these higher fields. I teamed with the inventor of an ultra-low
field detection device (the SQUID magnetometer, for which Dr. Clarke was nominated for a Nobel Prize)
that allows for increased contrast and thus the ability to image tissues to discriminate cancer from benign
at low field. I helped design the clinical aspects of all experiments, and oversaw tissue selection,
characterization and pathology comparison to the MR images generated by this technique.
4. McKenney JK, Simko J, Bonham M, True LD, Troyer D, Hawley S, Newcomb LF, Fazli L, Kunju
LP, Nicolas MM, Vakar-Lopez F, Zhang X, Carroll PR, Brooks JD; Canary/Early Detection Research
Network Prostate Active Surveillance Study Investigators, "The potential impact of reproducibility of
Gleason grading in men with early stage prostate cancer managed by active surveillance: a multiinstitutional study," J Urol 186(2): 465-9 (2011). We are developing and testing new ways of grading
prostate tumors to increase reproducibility and clinical utility. This paper was one of the first steps in this
process, and was designed to identify tumor patterns that are not diagnosed in a consistent manner under
current tumor grading paradigms.
5. Hayes GM, Simko J, Holochwost D, Kuchinsky K, Busch R, Misell L, Murphy EJ, Carroll PR, Chan
JM, Shinohara K, Hellerstein MK, "Regional Cell Proliferation in Microdissected Human Prostate
Specimens After Heavy Water-Labeling in vivo: Correlation With Prostate Epithelial Cells Isolated From
Seminal Fluid," Clin Cancer Res. 2012 May 2. [Epub ahead of print].
I helped design and perform the tissue collection and analyses in this clinical trial that showed the utility
of measuring deuterium in patient specimens. The concept takes advantage of increased deuterium
incorporation into proliferating tissues (i.e. cancer) that can be used in non-invasive diagnostic tools.
25
Jeff Simko
References to teaching ability:
DR. Soo-Jin Cho, Clinical Instructor, UCSF Department of Anatomic Pathology
DR. Tara Saunders, Clinical Fellow, UCSF Department of Anatomic Pathology
Dr. Anobel Odisho, Resident Physician, UCSF Department of Urology
DR. Han Lee, Assistant Professor, UCSF Department of Anatomic Pathology
DR. Mike Bonham, Medical Director, Oppenheimer Urologic Labs, Burlingame, CA
DR Sam Washington, Resident Physician, UCSF Departments of Surgery and Urology
26
Jeff Simko
Outside Referees:
Walter J. Curran, Jr., M.D.
Executive Director, Winship Cancer Institute of Emory University
Associate Vice President, Cancer, Woodruff Health Sciences Center
Lawrence W. Davis Chair of Radiation Oncology
Professor
Department of Radiation Oncology
Emory University School of Medicine
Department of Radiation Oncology
Emory University School of Medicine
1365 Clifton Road, N.E.
Atlanta, GA 30322
Tel: (404)-778-3473
Fax: (404) 778-4139
Email: wcurran@emory.edu
Adam Dicker, MD, PhD, Professor & Chair, Dept of Radiation Oncology
Jefferson Medical College of Thomas Jefferson University & Hospitals
Kimmel Cancer Center, an NCI designated Cancer Center
111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107
(215) 955-6700
(215) 503-0013 fax
email: adamdicker@mac.com
Lawrence True, MD and Professor Pathology
Room BB220
Dept of Pathology, Box 356100
1959 NE Pacific St.
University of Washington Medical Center
Seattle, WA, 98195-6100
Office: (206) 598-4027
FAX: (206) 598-3803
Pager (when in town) 206-344-0584
email: ltrue@uw.edu
Richard C. Friedberg, MD, PhD, FCAP
Chair, Department of Pathology
Medical Director, Baystate Reference Laboratories
Professor and Deputy Chairman
Department of Pathology
27
Jeff Simko
Tufts University School of Medicine
759 Chestnut Street
Springfield, MA 01199
413-794-4500
Fax 413-794-5893
email: richard.friedberg@baystatehealth.org
Colin Collins, PhD
Professor, Department of Urologic Sciences, University of British Columbia
Vancouver Prostate Centre
Jack Bell Research Centre
2660 Oak Street
Vancouver, BC V6H 3Z6
Phone: 604-875-4818
Fax: 604-875-5654
email: Colin Collins (ccollins@prostatecentre.com)
Waldman, Frederic, MD, PhD
Medical Director, Cancer Diagnostics
Quest Diagnostics Nichols Institute
Hematology/Oncology Department
33608 Ortega Highway
San Juan Capistrano, CA 92675
949-728-4008
Email: Frederic.M.Waldman@questdiagnostics.com
Internal Referees:
Peter Carroll, MD, MPH: Professor and Chair, UCSF Department of Urology
Mack Roach III, MD: Professor and Chair, UCSF Department of Radiation Oncology
Linda Ferrell, MD: Professor and Vice Chair, UCSF Department of Anatomic Pathology
Richard Jordan, DDS,PhD: Professor and Associate Dean of Research, UCSF Department of
Orofacial Sciences
28
`